Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The management of patients with Obstructive Chronic BronchoPneumopathy (OCBP) is based on a progression of therapeutic options and on a sensitization to physical activity.
For these patients selected on OCBP stage 2, the treatment options include Long Acting Beta-Agonist Bronchodilator (LABA) or Long Acting Muscarinic Antagonist Anticholinergic (LAMA) or both (LAMA+LABA).
The purpose of this study is to observe in common clinical practice the benefit of physical activity on quality of life, dyspnoea and walking distance for these patients under treatment (LABA and/or LAMA) and to determine whether these 3 medical strategies (LABA/LAMA/LABA+LAMA) benefit from physical activity.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in quality of life after 4 to 10 weeks of physical activity program | Evaluation of quality of life by specific questionnaires (VQ11, RICCI Test) and by specific parameters such as: spirometry, dyspnea, Body Mass Index (BMI), 6 minute Stepper Test (TS6), Body mass index, airflow Obstruction, Dyspnea and Exercise tolerance (BODE), O2 maximal Volume (VO2max) or Electrocardiogram (ECG). | Visit 1 before physical activity program and Visit 2 after 4 to 10 weeks of physical activity program |
| Measure | Description | Time Frame |
|---|---|---|
| Medical Research Council dyspnea scale (grade degree 0 to 4)activity | Grade Degree of breathlessness related to activities (o to 4) : 0 : Not troubled by breathlessness except on strenuous exercise
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with Obstructive Chronic BronchoPneumopathy (OCBP) stage ≥ 2
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gilles DEVOUASSOUX, MD, PhD | Contact | 33 4.26.73.29.47 | gilles.devouassoux@chu-lyon.fr | |
| Isabelle DELFOUR | Contact | 33 4.26.73.27.25 | isabelle.delfour@chu-lyon.fr |
| Name | Affiliation | Role |
|---|---|---|
| Gilles Devouassoux, MD | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Recruiting | Lyon | 69004 | France |
Not provided
Not provided
Not provided
Not provided
| Grade degree of dyspnea will be evaluated one time before and after the physical activity program an expected average of 10 weeks. |
| 6 Minute Walking Test (6MWT) (unit : meter) | The original purpose of the six minute walk was to test exercise tolerance in chronic respiratory disease and heart failure. The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. | 6MWT will be realized one time before and after the physical activity program an expected average of 10 weeks. |
| Actimetry by accelerometer (unit : number of body movement) | Actimetry by accelerometer to assess physical activity. Technically, an accelerometer consists of a device with a piezoelectric sensor that registers physical activity via body movement (acceleration) produced during a limited period of time. | Accelerometer will be installed one time before and after the physical activity program an expected average of 10 weeks. |